Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists of Central Illinois
mi
from
Decatur, IL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Oncology Specialists, SC
mi
from
Park Ridge, IL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Midwestern Regional Medical Center
mi
from
Zion, IL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Midwestern Regional Medical Center
mi
from
Zion, IL
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Central Indiana Cancer Centers
mi
from
Fishers, IN
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Central Indiana Cancer Centers
mi
from
Fishers, IN
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology of Indiana
mi
from
Indianapolis, IN
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Floyd Memorial Cancer Center of Indiana
mi
from
New Albany, IN
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Floyd Memorial Cancer Center of Indiana
mi
from
New Albany, IN
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ashland Bellefonte Cancer Center
mi
from
Ashland, KY
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ashland Bellefonte Cancer Center
mi
from
Ashland, KY
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Owsley Brown Frazier Cancer Center (OBFCC)
mi
from
Louisville, KY
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Owsley Brown Frazier Cancer Center (OBFCC)
mi
from
Louisville, KY
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Purchase Cancer Group
mi
from
Paducah, KY
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Purchase Cancer Group
mi
from
Paducah, KY
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Capitol Comprehensive Cancer Care Clinic
mi
from
Jefferson City, MO
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Capitol Comprehensive Cancer Care Clinic
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Arena Oncology Associates PC
mi
from
Lake Success, NY
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Arena Oncology Associates PC
mi
from
Lake Success, NY
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical College New York-Presbyterian Hospital Weill, Cornell Breast Center
mi
from
New York, NY
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College New York-Presbyterian Hospital Weill, Cornell Breast Center
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematolgy, PC
mi
from
Troy, NY
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematolgy, PC
mi
from
Troy, NY
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Oncology Partners Network, Ltd.
mi
from
Cincinnati, OH
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Oncology Partners Network, Ltd.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
MetroHealth Medical Center, Cancer Care Center
mi
from
Cleveland, OH
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
MetroHealth Medical Center, Cancer Care Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center Dept. of Hematology Oncology
mi
from
Oklahoma City, OK
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center Dept. of Hematology Oncology
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lancaster Cancer Center
mi
from
Lancaster, PA
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lancaster Cancer Center
mi
from
Lancaster, PA
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Allegheny General Hospital, Allegheny Cancer Center
mi
from
Pittsburgh, PA
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Allegheny General Hospital, Allegheny Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cookeville Regional Medical Center
mi
from
Cookeville, TN
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cookeville Regional Medical Center
mi
from
Cookeville, TN
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Center for Biomedical Research
mi
from
Knoxville, TN
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Center for Biomedical Research
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Thompson Cancer Survival Center Thompson Oncology Group
mi
from
Knoxville, TN
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Thompson Cancer Survival Center Thompson Oncology Group
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Cancer Institute
mi
from
Memphis, TN
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Cancer Institute
mi
from
Memphis, TN
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Austin, TX
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Austin, TX
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
El Paso Cancer Treatment Ctr - West
mi
from
El Paso, TX
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
El Paso Cancer Treatment Ctr - West
mi
from
El Paso, TX
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hope Oncology
mi
from
Richardson, TX
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hope Oncology
mi
from
Richardson, TX
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Care Network of South Texas-HOAST
mi
from
San Antonio, TX
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Care Network of South Texas-HOAST
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
East Texas Medical Center Cancer Institute, Tyler Hematology Oncology
mi
from
Tyler, TX
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
East Texas Medical Center Cancer Institute, Tyler Hematology Oncology
mi
from
Tyler, TX
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mater Private Centre for HOCA
mi
from
South Brisbane,
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mater Private Centre for HOCA
mi
from
South Brisbane,
Click here to add this to my saved trials
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR)
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR)
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
University of Chicago /ID# 169231
mi
from
Chicago, IL
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
University of Chicago /ID# 169231
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Washington University School /ID# 169177
mi
from
Saint Louis, MO
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Washington University School /ID# 169177
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering /ID# 201016
mi
from
New York, NY
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering /ID# 201016
mi
from
New York, NY
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Gabrail Cancer Center Research /ID# 168756
mi
from
Canton, OH
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Gabrail Cancer Center Research /ID# 168756
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Oklahoma University /ID# 200937
mi
from
Oklahoma City, OK
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Oklahoma University /ID# 200937
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233
mi
from
Nashville, TN
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
Baylor University /ID# 169860
mi
from
Houston, TX
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
Baylor University /ID# 169860
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated:  12/31/1969
MD Anderson Cancer Center /ID# 169232
mi
from
Houston, TX
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Status: Enrolling
Updated: 12/31/1969
MD Anderson Cancer Center /ID# 169232
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
Bellevue Hospital Center
mi
from
New York, NY
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
Bellevue Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
What Matters Most: Choosing the Right Breast Cancer Surgery for You
Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage III Breast Cancer
1) Adenovirus p53 Infected DC Vaccine For Breast Cancer, 2) Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated:  12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage III Breast Cancer
1) Adenovirus p53 Infected DC Vaccine For Breast Cancer, 2) Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated: 12/31/1969
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer
Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer
Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials